Payment overview · 2025
General Payments
$729.72
10 reported records · 6 companies
Healthcare provider profile · identity verified
Paula Stowell, ARNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · ST AUGUSTINE, FL · NPI 1891714564
Verified facts
What the public records show
CMS Open Payments records show Paula Stowell, ARNP received $729.72 in general payments during 2025 across 10 reported records.
Vanda Pharmaceuticals Inc. accounted for 34.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $254.46 | 34.9% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $231.50 | 31.7% | 2 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $113.85 | 15.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $87.34 | 12.0% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $22.40 | 3.1% | 1 | 2025 |
| Solta Medical, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $20.17 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $729.72 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $254.46 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $123.97 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $107.53 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $43.67 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $43.67 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $22.40 | 1 | 2025 |
Source payment records
|
|||||
| CLEAR+BRILLIANT Normalized: clear brilliant |
Not specified | Solta Medical, a division of Bausch Health US, LLC | $20.17 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Alprazolam | Alprazolam | 1492 | 279 |
| Clonazepam | Clonazepam | 930 | 184 |
| Trazodone Hcl | Trazodone Hcl | 725 | 238 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 589 | 281 |
| Fluoxetine Hcl | Fluoxetine Hcl | 397 | 123 |
| Bupropion Xl | Bupropion Hcl | 395 | 132 |
| Gabapentin | Gabapentin | 373 | 157 |
| Buspirone Hcl | Buspirone Hcl | 372 | 136 |
| Lorazepam | Lorazepam | 366 | 62 |
| Diazepam | Diazepam | 355 | 59 |
| Sertraline Hcl | Sertraline Hcl | 342 | 108 |
| Amitriptyline Hcl | Amitriptyline Hcl | 321 | 94 |
| Lamotrigine | Lamotrigine | 318 | 95 |
| Citalopram Hbr | Citalopram Hydrobromide | 308 | 102 |
| Zolpidem Tartrate | Zolpidem Tartrate | 299 | 44 |
| Escitalopram Oxalate | Escitalopram Oxalate | 281 | 97 |
| Quetiapine Fumarate | Quetiapine Fumarate | 277 | 83 |
| Duloxetine Hcl | Duloxetine Hcl | 267 | 88 |
| Atorvastatin Calcium | Atorvastatin Calcium | 260 | 124 |
| Lisinopril | Lisinopril | 224 | 114 |
| Levothyroxine Sodium | Levothyroxine Sodium | 223 | 108 |
| Memantine Hcl | Memantine Hcl | 218 | 78 |
| Donepezil Hcl | Donepezil Hcl | 209 | 78 |
| Omeprazole | Omeprazole | 207 | 102 |
| Temazepam | Temazepam | 201 | 34 |
| Divalproex Sodium Er | Divalproex Sodium | 198 | 65 |
| Bupropion Hcl | Bupropion Hcl | 197 | 85 |
| Mirtazapine | Mirtazapine | 175 | 56 |
| Ezetimibe | Ezetimibe | 170 | 84 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 165 | 42 |
| Losartan Potassium | Losartan Potassium | 159 | 87 |
| Metformin Hcl Er | Metformin Hcl | 151 | 85 |
| Fenofibrate | Fenofibrate | 148 | 71 |
| Aripiprazole | Aripiprazole | 142 | 41 |
| Azithromycin | Azithromycin | 137 | 100 |
| Amlodipine Besylate | Amlodipine Besylate | 132 | 77 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 130 | 24 |
| Pantoprazole Sodium | Pantoprazole Sodium | 130 | 74 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 125 | 59 |
| Risperidone | Risperidone | 121 | 31 |
| Tizanidine Hcl | Tizanidine Hcl | 114 | 48 |
| Paroxetine Hcl | Paroxetine Hcl | 113 | 36 |
| Methylphenidate Hcl | Methylphenidate Hcl | 111 | 26 |
| Metoprolol Succinate | Metoprolol Succinate | 107 | 54 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 104 | 44 |
| Pioglitazone Hcl | Pioglitazone Hcl | 101 | 51 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 97 | 46 |
| Topiramate | Topiramate | 87 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 83 | 40 |
| Alendronate Sodium | Alendronate Sodium | 79 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 75 | 40 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 73 | 36 |
| Eliquis | Apixaban | 72 | 35 |
| Benztropine Mesylate | Benztropine Mesylate | 71 | 21 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 69 | 60 |
| Montelukast Sodium | Montelukast Sodium | 69 | 40 |
| Meloxicam | Meloxicam | 68 | 32 |
| Famotidine | Famotidine | 65 | 42 |
| Propranolol Hcl | Propranolol Hcl | 61 | 21 |
| Invokana | Canagliflozin | 58 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 56 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 48 | 25 |
| Furosemide | Furosemide | 47 | 29 |
| Fluconazole | Fluconazole | 43 | 31 |
| Levetiracetam | Levetiracetam | 43 | 12 |
| Prednisone | Prednisone | 43 | 33 |
| Clonidine Hcl | Clonidine Hcl | 42 | 20 |
| Metformin Hcl | Metformin Hcl | 41 | 28 |
| Venlafaxine Hcl | Venlafaxine Hcl | 41 | 14 |
| Atenolol | Atenolol | 39 | 17 |
| Simvastatin | Simvastatin | 39 | 18 |
| Carvedilol | Carvedilol | 37 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 37 | 34 |
| Baclofen | Baclofen | 36 | 17 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 36 | 18 |
| Olanzapine | Olanzapine | 36 | 14 |
| Vraylar | Cariprazine Hcl | 36 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 35 | 25 |
| Haloperidol | Haloperidol | 35 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 35 | 26 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 35 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 35 | 16 |
| Dicyclomine Hcl | Dicyclomine Hcl | 33 | 17 |
| Finasteride | Finasteride | 33 | 22 |
| Bupropion Hcl Sr | Bupropion Hcl | 32 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 32 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 31 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 25 |
| Doxepin Hcl | Doxepin Hcl | 30 | suppressed |
| Ibuprofen | Ibuprofen | 30 | 14 |
| Methocarbamol | Methocarbamol | 29 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 29 | 21 |
| Invega Sustenna | Paliperidone Palmitate | 27 | suppressed |
| Celecoxib | Celecoxib | 26 | 13 |
| Promethazine Hcl | Promethazine Hcl | 26 | 17 |
| Metoclopramide Hcl | Metoclopramide Hcl | 25 | 11 |
| Naltrexone Hcl | Naltrexone Hcl | 25 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 24 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 23 | 13 |
| Lithium Carbonate | Lithium Carbonate | 23 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 23 | 20 |
| Sildenafil Citrate | Sildenafil Citrate | 23 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 23 | suppressed |
| Potassium Chloride | Potassium Chloride | 22 | 16 |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Cephalexin | Cephalexin | 20 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | 11 |
| Acyclovir | Acyclovir | 19 | 11 |
| Allopurinol | Allopurinol | 19 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 18 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Spironolactone | Spironolactone | 16 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 13 |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Modafinil | Modafinil | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Letrozole | Letrozole | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Armour Thyroid | Thyroid,pork | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $729.72 · 10 records | Vanda Pharmaceuticals Inc. | CAPLYTA, CLEAR+BRILLIANT, Cologuard Collection Kit, FANAPT, Ozempic, The Cologuard Plus Collection Kit, Wegovy | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error